Loading...
TNGX logo

Tango Therapeutics, Inc.NasdaqGM:TNGX 株式レポート

時価総額 US$2.9b
株価
US$21.08
US$31.9
33.9% 割安 内在価値ディスカウント
1Y1,015.3%
7D-17.4%
ポートフォリオ価値
​
表示

Tango Therapeutics, Inc.

NasdaqGM:TNGX 株式レポート

時価総額：US$2.9b

Tango Therapeutics（TNGX）株式概要

精密腫瘍学企業であるタンゴ・セラピューティクス社は、アンメット・メディカル・ニーズのある特定の患者集団における薬剤の発見と開発に注力している。 詳細

TNGX ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長2/6
過去の実績0/6
財務の健全性6/6
配当金0/6

報酬

収益は年間63.58%増加すると予測されています

リスク分析

過去1年間で株主の希薄化は大幅に進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

US市場と比較した過去 3 か月間の株価の変動


TNGX Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tango Therapeutics, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Tango Therapeutics
過去の株価
現在の株価US$21.08
52週高値US$28.41
52週安値US$1.72
ベータ1.22
1ヶ月の変化-20.12%
3ヶ月変化70.69%
1年変化1,015.34%
3年間の変化502.29%
5年間の変化88.72%
IPOからの変化106.06%

最新ニュース

Seeking Alpha • May 17

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Summary Tango Therapeutics is downgraded from "Buy" to "Hold" due to a major, unproven strategy shift for vopimetostat. The company now prioritizes combination trials of vopimetostat with RAS[ON] inhibitors for 1st-line MTAP-del pancreatic cancer, with pivotal trial design pending new data. Upcoming catalysts include phase 1/2 data for vopimetostat in lung cancer and TNG456 in glioblastoma, but outcomes remain uncertain. With $379.8M cash on hand, the company has enough to fund its operations through 2028. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 17

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Summary Tango Therapeutics is downgraded from "Buy" to "Hold" due to a major, unproven strategy shift for vopimetostat. The company now prioritizes combination trials of vopimetostat with RAS[ON] inhibitors for 1st-line MTAP-del pancreatic cancer, with pivotal trial design pending new data. Upcoming catalysts include phase 1/2 data for vopimetostat in lung cancer and TNG456 in glioblastoma, but outcomes remain uncertain. With $379.8M cash on hand, the company has enough to fund its operations through 2028. Read the full article on Seeking Alpha
分析記事 • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
分析記事 • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
分析記事 • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
分析記事 • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
分析記事 • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
分析記事 • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
分析記事 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
分析記事 • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
分析記事 • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
分析記事 • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
分析記事 • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
分析記事 • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
分析記事 • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
分析記事 • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
分析記事 • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
分析記事 • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
分析記事 • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
分析記事 • May 28

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jan 06

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

株主還元

TNGXUS BiotechsUS 市場
7D-17.4%-3.0%-0.3%
1Y1,015.3%32.9%26.7%

業界別リターン: TNGX過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: TNGX過去 1 年間で23.3 % の収益を上げたUS市場を上回りました。

価格変動

Is TNGX's price volatile compared to industry and market?
TNGX volatility
TNGX Average Weekly Movement15.1%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

安定した株価: TNGXの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: TNGXの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2017137Malte Peterswww.tangotx.com

タンゴ・セラピューティクス社はプレシジョン・オンコロジー企業であり、アンメット・メディカル・ニーズのある特定の患者集団における薬剤の発見と開発に注力している。同社はメチルチオアデノシン-協同性タンパク質アルギニンメチルトランスフェラーゼ5（PRMT5）阻害剤を開発しており、膵臓癌と肺癌の治療薬として臨床第1/2相試験中のTNG462や、膠芽腫の治療薬として脳浸透性PRMT5阻害剤TNG456などがある。セリン・スレオニンキナーゼ（STK）11機能喪失変異の免疫回避効果を逆転させ、肺がんを治療するための共抑制因子エレメント-1サイレンシング転写阻害剤TNG260を開発中である。同社は2017年に設立され、マサチューセッツ州ボストンに本社を置いている。

Tango Therapeutics, Inc. 基礎のまとめ

Tango Therapeutics の収益と売上を時価総額と比較するとどうか。
TNGX 基礎統計学
時価総額US$2.94b
収益（TTM）-US$107.23m
売上高(TTM)US$56.99m
53.5x
P/Sレシオ
-28.4x
PER（株価収益率

TNGX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
TNGX 損益計算書（TTM）
収益US$56.99m
売上原価US$129.26m
売上総利益-US$72.26m
その他の費用US$34.97m
収益-US$107.23m

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）-0.74
グロス・マージン-126.80%
純利益率-188.15%
有利子負債／自己資本比率0%

TNGX の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/20 03:00
終値2026/05/20 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Tango Therapeutics, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.